HIV

ACCELERATE

Post Date: 
2022-09-08
   |   
Countries: 
Under the directives of PEPFAR, with support from USAID, and in collaboration with NACO, the ACCELERATE program provides HIV/AIDS services for high-risk populations including key populations affected by HIV throughout India and technical assistance (TA) to the national, state, and district...

Mitr Clinic - Pride and Beyond

Post Date: 
2022-09-08
USAID and PEPFAR supported Program ACCELERATE, implemented by Johns Hopkins University School of Medicine (JHU SOM) in partnership with YRG Care, The Fenway Institute and the Blue Lotus Advisory under the leadership of National AIDS Control Organisation (NACO) and State AIDS Control Societies (SACS...

Kidaba Thawai (Fearless Souls) Documentary

Post Date: 
2022-09-08
   |   
Countries: 
The documentary Kidaba Thawai is based on ACCELERATE's intervention - an Adolescent Friendly Health Center (AFHC) in Imphal, Manipur. The documentary discusses AFHC's comprehensive health care delivery model (HIV and non-HIV services) which contributes to the holistic development of adolescents. A...

“Bridging the Gaps”: Understanding the Barriers and Facilitators in the Tuberculosis Prevention Care Cascade for Optimizing Isoniazid Preventive Therapy Uptake among Adults Living with HIV in India, a Mixed-Method Approach

Post Date: 
2021-11-02
   |   
Countries: 
   |   
Clinical Sites: 
PURPOSE: The isoniazid preventive therapy policy has achieved limited success in low and middle-income countries. With limited empirical research exploring the barriers to suboptimal IPT uptake, it is important to understand this knowledge gap. Also, limited programmatic strategies exist to address...

A5362: A Phase IIc Trial of Clofazimine- and Rifapentine-Containing Treatment Shortening Regimens in Drug-Susceptible Tuberculosis: The CLO-FAST Study

Post Date: 
2021-06-15
   |   
Countries: 
   |   
Clinical Sites: 
Primary Hypothesis A 3-month regimen of rifapentine/isoniazid/pyrazinamide/ethambutol (PHZE) with clofazimine (CFZ) dosed as 100 mg daily with a 2-week 300 mg daily loading dose (Arm 1) will demonstrate early efficacy (time to 12-week liquid culture conversion) relative to standard of care (SOC) (...

P2026: Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs during Pregnancy and Postpartum

Post Date: 
2021-05-18
   |      |   
Clinical Sites: 
IMPAACT P1026s, the predecessor of this study, was first approved in 2003. P1026s enrolled over 1000 pregnant/postpartum women, studied the PK of more than 25 HIV and TB drugs in these women and published 27 manuscripts presenting these data. P1026s data was cited in 32% of the 76 perinatal...

The Pharmacokinetics, Safety and Acceptability of New Child-Friendly Formulations of Clofazimine and Moxifloxacin in Children Routinely Treated for Rifampicin-Resistant Tuberculosis (CATALYST)

Post Date: 
2021-04-26
   |      |   
Clinical Sites: 
PK, safety and acceptability data and practical guidance on the optimal dosing of new more child-friendly formulations of moxifloxacin and clofazimine in children are urgently needed to inform their current and future use in children with Rifampicin-Resistant TB (RR-TB). Both medications have a key...

Effect of Neighborhoods and Peer Networks on substance use and violence among adolescents living with and without HIV in India

Post Date: 
2021-01-28
   |   
Countries: 
   |   
Clinical Sites: 
Purpose of the study: A strong bidirectional association exists between substance use, various forms of violence and HIV. Substance use accounts for 0.8% of the burden of disease measured in disability adjusted life years (DALYs) among adolescents in South Asia. Violence among adolescents living...

Impact of Tuberculosis Infection on HIV-1 Antibody Response (NWCS501)

Post Date: 
2020-12-05
   |   
Countries: 
   |   
Clinical Sites: 
Study Objective: Compare longitudinal HIV-1 antibody responses among HIV-1 infected participants that either did or did not develop active TB enrolled in ACTG 5274 and ACTG 5279 Study Design: Longitudinal antibody responses will be examined among select participants in A5274 who have plasma samples...

Prevalence of Risk Factors for Lung Cancer and Facilitators and Barriers for Tobacco Cessation among People Living with HIV

Post Date: 
2020-04-01
   |   
Countries: 
   |   
Clinical Sites: 
India has the world’s third largest HIV epidemic, with 2.1 million people currently living with HIV and an additional 90,000 new infections each year.[29] At the same time, expansion of the HIV response under India’s premier governmental agency - the National AIDS Control Organization (NACO), has...

The Sentinel Research Network of IeDEA: A Prospective Cohort among People Living with HIV

Post Date: 
2020-03-12
   |   
Clinical Sites: 
This study is nested within the TREAT Asia HIV Observational Database initiative. The global scale up of antiretroviral therapy (ART) has significantly improved the immune recovery and life expectancy of people living with HIV (PLHIV). However, PLHIV on long-term ART now face health challenges...

Hybrid Trial for Alcohol Reduction among People with TB and HIV in India

Post Date: 
2020-02-12
   |   
Countries: 
   |   
Clinical Sites: 
Dr. Geetanjali Chander is PI and Dr. Kakrani is local site PI at DY Patil Medical College for this study. The highest incidence of tuberculosis disease (TB) in the world is in India, accounting for 27% of all new cases globally, with approximately 86,000 among persons with HIV (PWH). Unhealthy...

Pregnancy Associated Immune Responses to Tuberculosis and HIV in India and South Africa (PARTHISA)

Post Date: 
2020-01-14
   |   
Countries: 
   |   
Clinical Sites: 
Dr. Jyoti Mathad is Co-PI of this study. Purpose: Tuberculosis (TB) is a leading cause of maternal mortality, especially among HIV-infected women. Women are most likely to develop active TB during and immediately after pregnancy. The immunologic conditions responsible for this phenomenon are not...

Long-Acting/Extended Release Antiretroviral Resource Program (LEAP)

Post Date: 
2019-12-30
Learn more about this effort to foster development of long-lasting therapies for illnesses that require taking medications long-term

Markers of Lung Impairment in HIV-TB Coinfected Indian Adults

Post Date: 
2019-12-11
   |   
Countries: 
   |   
Clinical Sites: 
Objectives/Aims We will compare the degree of lung impairment between HIV-TB co-infected adults (HIV-TB group) and TB cases without HIV co-infection (TB group) who successfully complete TB therapy. We hypothesize that the HIV-TB group will have a greater degree of lung...

A5300B/I2003B: Protecting Households On Exposure to Newly Diagnosed Index Multidrug-Resistant Tuberculosis Patients (PHOENIx)

Post Date: 
2019-08-19
   |   
Countries: 
   |   
Clinical Sites: 
Dr. Amita Gupta is Protocol Co-chair for this multinational clinical trial. BACKGROUND The World Health Organization (WHO) estimates that there were 480,000 incident cases of MDR-TB globally in 2015. MDR-TB has been shown to be almost twice as common in TB...

A5300B/I2003B: Protecting Households On Exposure to Newly Diagnosed Index Multidrug-Resistant Tuberculosis Patients (PHOENIx)

Post Date: 
2019-08-19
   |   
Countries: 
   |   
Clinical Sites: 
Dr. Amita Gupta is Protocol Co-chair for this multinational clinical trial. BACKGROUND The World Health Organization (WHO) estimates that there were 480,000 incident cases of MDR-TB globally in 2015. MDR-TB has been shown to be almost twice as common in TB...

Visual Field Loss in HIV-Positive Patients of Non-Infectious HIV Retinopathy

Post Date: 
2019-06-02
   |   
Countries: 
   |   
Clinical Sites: 
New study will assess HIV+ patients and determine the prevalence of visual field loss due to noninfectious HIV retinopathy

Immune Correlates of LTBI in HIV-exposed Infants

Post Date: 
2019-04-29
   |   
Countries: 
About 2 billion people worldwide harbor asymptomatic latent TB infection (LTBI), activation of which results in progression to TB disease. In areas of high tuberculosis (TB) prevalence, infants and young children have a 3-fold higher risk of progression and death from TB at age < 5 years...

P2010: Phase III Study of the Virologic Efficacy and Safety of Dolutegravir-Containing versus Efavirenz-Containing Antiretroviral Therapy Regimens in HIV-1-Infected Pregnant Women and their Infants “VESTED”

Post Date: 
2019-02-06
   |   
Countries: 
   |   
Clinical Sites: 
This study was terminated September 2, 2021 Full Title: P2010: Phase III Study of the Virologic Efficacy and Safety of Dolutegravir-Containing versus Efavirenz-Containing Antiretroviral Therapy Regimens in HIV-1-Infected Pregnant Women and their Infants “...

Pages

Clinical and Immunological Markers of Pulmonary Impairment among People with HIV(PWH) in India

Post Date: 
2022-05-12
   |   
Countries: 
Publication: 
Open Forum Infectious Diseases
Background Despite anti-retroviral therapy, chronic lung diseases remain an important source of morbidity and mortality in people with HIV (PWH). We sought to identify clinical and immunological markers of pulmonary impairment among PWH in India. Methods 210 adult PWH receiving antiretroviral...

A randomized clinical trial of HPV test-and-treat as compared to cytology-based screening for prevention of cervical cancer among women living with HIV: AIDS Clinical Trials Group Protocol A5282

Post Date: 
2022-05-03
Publication: 
Clinical Infectious Diseases
Background Cytology-based cervical cancer screening followed by confirmation and treatment of biopsy-proven high-grade squamous intraepithelial (bHSIL), is difficult to implement in resource-constrained settings. We hypothesized that high-risk human papillomavirus (hrHPV) testing followed by...

Regional Differences in Risk of Recurrent Falls Among Older U.S. Women and Men with HIV in the HIV Infection, Aging, and Immune Function Long-Term Observational Study

Post Date: 
2022-05-03
   |   
Countries: 
Publication: 
AIDS Research and Human Retroviruses
Geographic location was a strong predictor of falls among women with and without HIV in the Women's Interagency HIV Study. We examined regional variation in falls in a more geographically diverse cohort of older people with HIV (PWH) and explored whether physical activity, sex, or body–mass...

Participant Perspectives and Experiences Following an Intensively Monitored Antiretroviral Pause in the United States: Results from the AIDS Clinical Trials Group A5345 Biomarker Study

Post Date: 
2022-05-03
Publication: 
AIDS Research and Human Retroviruses
The AIDS Clinical Trials Group A5345 study (NCT03001128) included an intensively monitored antiretroviral pause (IMAP), during which participants living with HIV temporarily stopped antiretroviral treatment (ART) in an effort to identify biomarkers that could predict HIV rebound. We evaluated...

The impact of short term Antiretroviral Therapy (ART) interruptions on longer term maternal health outcomes-A randomized clinical trial

Post Date: 
2021-07-13
   |   
Countries: 
Publication: 
PLoS One
Background: Given well documented challenges faced by pregnant women living with HIV taking lifetime ART, it is critical to understand the impact of short-term ART exposure followed by treatment interruption on maternal health outcomes. Methods: HIV+ breastfeeding (BF) and Formula Feeding (FF)...

Nevirapine pharmacokinetics in HIV-infected persons receiving rifapentine and isoniazid for TB prevention

Post Date: 
2020-11-26
   |   
Countries: 
Publication: 
The Journal of Antimicrobial Chemotherapy
Background: The use of rifamycin antibiotics for TB prevention carries a risk of detrimental drug-drug interactions with concomitantly used ART. Objectives: To evaluate the interaction of the antiretroviral drug nevirapine in combination with 4 weeks of daily rifapentine and isoniazid for TB...

The burden of anxiety among people living with HIV during the COVID-19 pandemic in Pune, India

Post Date: 
2020-10-23
   |   
Countries: 
Publication: 
BMC Public Health
Introduction: Globally, India has the third largest population of people living with HIV (PLHIV) and the second highest number of COVID-19 cases. Anxiety is associated with antiretroviral therapy (ART) nonadherence. It is crucial to understand the burden of anxiety and its sources among Asian...

Individual and Composite Adverse Pregnancy Outcomes in a Randomized Trial on Isoniazid Preventative Therapy Among Women Living With HIV

Post Date: 
2020-09-30
Publication: 
Clinical Infectious Diseases
Background: IMPAACT P1078, a randomized non-inferiority study designed to compare safety of starting isoniazid preventive therapy (IPT) in women with HIV during pregnancy or after delivery, showed that IPT during pregnancy increased the risk of composite adverse pregnancy outcomes, but not...

Pharmacokinetics and drug-drug interactions of isoniazid and efavirenz in pregnant women living with HIV in high TB incidence settings: importance of genotyping

Post Date: 
2020-09-09
   |   
Countries: 
Publication: 
Clinical Pharmacology and Therapeutics
World Health Organization guidelines recommend that individuals living with HIV receive ≥6 months of isoniazid preventive therapy, including pregnant women.

The effect of TB treatment on health-related quality of life for people with advanced HIV

Post Date: 
2020-09-01
   |   
Countries: 
Publication: 
International Journal of Tuberculosis and Lung Disease
BACKGROUND: Study A5274 was an open-label trial of people with HIV (PLHIV) with CD4 cell count <50 cells/µL who were randomized to empirical TB treatment vs. isoniazid preventive therapy (IPT) in addition to antiretroviral therapy (ART). We evaluated health-related quality of life (HRQoL) by...

An Evaluation of Baseline Kidney Function in the REPRIEVE Trial of Pitavastatin in Human Immunodeficiency Virus

Post Date: 
2020-08-01
Publication: 
The Journal of Infectious Diseases
Background Chronic kidney disease is a common comorbid condition among persons living with human immunodeficiency virus (PWH). We characterized baseline kidney function in the REPRIEVE (Randomized Trial to Prevent Vascular Events in HIV) trial cohort. Methods REPRIEVE enrolled PWH with low to...

Effects of Pregnancy and Isoniazid Preventive Therapy on M. tuberculosis Interferon Gamma Response Assays in Women with HIV

Post Date: 
2020-07-28
   |   
Countries: 
Publication: 
Clinical Infectious Diseases
944 women with HIV participating in a randomized, double-blind, placebo-controlled study comparing 28 weeks of IPT antepartum versus postpartum, were tested by QuantiFERON-gold-in-tube (QGIT) antepartum and by QGIT and tuberculin skin test (TST) at delivery and postpartum.

A mobile health-facilitated behavioral intervention for community health workers improves exclusive breastfeeding and early infant HIV diagnosis in India: A cluster randomized trial

Post Date: 
2020-07-03
   |   
Countries: 
   |   
Clinical Sites: 
Publication: 
Journal of the International AIDS Society
When community health workers used a mobile health intervention with HIV+ women to deliver care, there was a higher uptake of exclusive breastfeeding at two months and early infant HIV diagnosis at six weeks

Trends and gender differences in access to HIV care with scale up of national HIV treatment guidelines in India

Post Date: 
2020-06-24
   |   
Countries: 
Publication: 
Journal of the International Association of Providers of AIDS Care
Test and treat is the current global standard, yet sex differences persist in access to HIV care. We assessed the differences in presentation and antiretroviral therapy (ART) uptake by sex and ART-eligibility period among ART-naive adults registered at a public ART center in India. Four ART...

Acceptability and Feasibility of a Behavioral and Mobile Health Intervention (COMBIND) Shown to Increase Uptake of Prevention of Mother to Child Transmission (PMTCT) Care in India

Post Date: 
2020-05-24
   |   
Countries: 
Publication: 
BMC Public Health
A cluster-randomized trial recently demonstrated that an integrated behavioral and mobile technology intervention improved uptake of key components of a Prevention of Mother to Child Transmission (PMTCT) Option B+ program, among HIV- infected pregnant/breastfeeding women in India.

Once-weekly Rifapentine and Isoniazid for Tuberculosis Prevention in Patients With HIV Taking Dolutegravir-Based Antiretroviral Therapy: A Phase 1/2 Trial

Post Date: 
2020-03-30
Publication: 
Lancet HIV
Short-course preventive therapy with 12 doses of once-weekly rifapentine (900 mg) plus isoniazid (900 mg) could greatly improve tuberculosis control, especially in areas with high co-endemicity with HIV.

TB prevention strategies and unanswered questions for pregnant and postpartum women living with HIV: the need for improved evidence

Post Date: 
2020-03-23
Publication: 
Journal of the International AIDS Society
World TB Day viewpoint on the need for more data about TB treatment for pregnant and postpartum women in J Int AIDS Soc by Drs. Jyoti Mathad and Amita Gupta.

HIV, Pregnancy, and Isoniazid Preventive Therapy. Reply

Post Date: 
2020-03-19
   |   
Countries: 
Publication: 
The New England Journal of Medicine
Gupta et al. (Oct. 3 issue)1 report a higher incidence of adverse pregnancy outcomes among women with human immunodeficiency virus (HIV) infection who were exposed to isoniazid preventive therapy (IPT) during the second and third trimesters than among those not exposed to IPT during pregnancy. From...

Hepatotoxicity and Liver-Related Mortality in Women of Child-Bearing Potential Living With HIV and High CD4 Counts Initiating Efavirenz-Containing Regimens

Post Date: 
2020-03-12
Publication: 
Clinical Infectious Diseases
Background: Severe hepatotoxicity in people with HIV receiving efavirenz (EFV) has been reported. We assessed the incidence and risk factors of hepatotoxicity in women of child-bearing age initiating EFV-containing regimens. Methods: In the PROMISE trial, ART-naïve pregnant women with HIV and CD4...

High prevalence of late presentation of ART-naïve perinatally infected children for care in Pune, India

Post Date: 
2020-02-19
   |   
Countries: 
   |   
Clinical Sites: 
Publication: 
AIDS Care
AIDS Care : There is an urgent need to identify strategies that improve linkage of perinatally infected ART-naïve children to care, and earlier than what is currently observed.

Pages